Dextran-Coated Iron Oxide Nanoparticles Loaded with 5-Fluorouracil for Drug-Delivery Applications.
5-Fluorouracil
Caco-2 cells
anti-proliferative effect
dextran
drug-delivery system
iron oxide nanoparticles
toxicity
Journal
Nanomaterials (Basel, Switzerland)
ISSN: 2079-4991
Titre abrégé: Nanomaterials (Basel)
Pays: Switzerland
ID NLM: 101610216
Informations de publication
Date de publication:
06 Jun 2023
06 Jun 2023
Historique:
received:
29
04
2023
revised:
27
05
2023
accepted:
04
06
2023
medline:
27
6
2023
pubmed:
27
6
2023
entrez:
27
6
2023
Statut:
epublish
Résumé
This study aims to design and test different formulations composed of dextran-coated iron oxide nanoparticles (IONPs) loaded with 5-Fluorouracil (5-FU) with varying nanoparticle:drug ratios on colorectal cancer cells. The stable suspension of IONPs s was synthesized by the adapted co-precipitation method. The stable suspension of IONPs was mixed with a solution of dextran and 5-FU solubilized in a saline solution. The final suspensions with optimized ratios of IONP:5-FU in the final suspension were 0.5:1, 1:1, and 1.5:1. The information on the morphology and size distribution of the IONPs suspension and IONP loads with 5-FU was obtained using scanning electron microscopy (SEM). The presence of 5-FU and dextran on the surface of the IONPs was highlighted by energy-dispersive X-ray spectroscopy (EDS) studies. The determination of the surface charge of the nanoparticles in the final suspensions of IONP:5-FU was achieved by measuring the zeta potential (ζ). The hydrodynamic diameter of the resulting suspensions of IONP:5-FU was determined by dynamic light scattering (DLS). A cytocompatibility analysis was performed using Caco-2 (human epithelial colorectal adenocarcinoma) cells. In this research, our goal was to find a relationship between the formulation ratio of nanoparticles and drug, and the cellular response after exposure, as a strategy to increase the efficacy of this drug-delivery system. The nanoparticle uptake and antitumor activity, including modulation of oxidative stress, apoptosis, and proliferation biomarkers, were analyzed. The present study showed that the nanoformulation with the ratio IONP:5-FU 1.5:1 had the highest anti-tumor efficiency. Moreover, decreased MCM-2 expression in Caco-2 cells exposed to dextran-coated iron oxide nanoparticles loaded with 5-FU was demonstrated for the first time.
Identifiants
pubmed: 37368241
pii: nano13121811
doi: 10.3390/nano13121811
pmc: PMC10300921
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Romanian Ministry of Research, Innovation and Digitalization
ID : Core Program PC1- PN23080101
Références
Oncotarget. 2019 Mar 12;10(21):2022-2029
pubmed: 31007845
Nanobiomedicine (Rij). 2014 Jan 1;1:2
pubmed: 30023013
Int J Cancer. 2018 Aug 15;143(4):921-930
pubmed: 29524226
Oncol Lett. 2014 Aug;8(2):699-704
pubmed: 25013487
Int J Biol Macromol. 2019 Jul 1;132:506-513
pubmed: 30951773
Nanomaterials (Basel). 2018 Jul 05;8(7):
pubmed: 29976868
Cancer Manag Res. 2022 Jan 23;14:273-285
pubmed: 35115827
Int J Nanomedicine. 2019 Aug 19;14:6661-6678
pubmed: 31695362
Oncol Rep. 2006 Apr;15(4):875-82
pubmed: 16525674
Mol Med. 2022 Oct 27;28(1):128
pubmed: 36303105
Prog Biomater. 2018 Dec;7(4):297-306
pubmed: 30565175
Cancers (Basel). 2018 Jan 30;10(2):
pubmed: 29385712
Chem Cent J. 2012 Mar 13;6:17
pubmed: 22410001
AAPS PharmSciTech. 2008;9(4):1092-6
pubmed: 18850275
Ther Adv Med Oncol. 2018 Jun 18;10:1758835918780140
pubmed: 29977352
J Cancer Res Ther. 2018 Dec;14(Supplement):S1141-S1147
pubmed: 30539860
Int J Nanomedicine. 2014 May 06;9 Suppl 1:51-63
pubmed: 24872703
World J Gastrointest Oncol. 2019 May 15;11(5):348-366
pubmed: 31139306
Front Nutr. 2021 Aug 24;8:690663
pubmed: 34504859
Eur J Pharm Sci. 2003 Aug;19(5):355-62
pubmed: 12907286
Pharmaceutics. 2023 Jan 04;15(1):
pubmed: 36678806
Eur J Pharm Biopharm. 2021 Aug;165:127-148
pubmed: 33992754
Am J Epidemiol. 2020 Jun 1;189(6):543-553
pubmed: 31971226
Cancers (Basel). 2020 May 29;12(6):
pubmed: 32486076
Toxicol In Vitro. 2013 Mar;27(2):954-63
pubmed: 23357416
Colloids Surf B Biointerfaces. 2014 Apr 1;116:745-50
pubmed: 24529474
Int J Nanomedicine. 2017 Apr 19;12:3207-3220
pubmed: 28458541
Eur J Pharm Biopharm. 2007 Nov;67(3):621-31
pubmed: 17533123
Nat Med. 2023 Jan;29(1):127-134
pubmed: 36646802
Chem Rev. 2008 Jun;108(6):2064-110
pubmed: 18543879
Toxicol In Vitro. 2016 Dec;37:189-200
pubmed: 27638054
ACS Omega. 2021 Jul 28;6(31):20192-20204
pubmed: 34395970
Surg Case Rep. 2021 Jun 28;7(1):152
pubmed: 34181132
Cell Death Dis. 2016 Feb 04;7:e2087
pubmed: 26844701
Redox Biol. 2017 Apr;11:613-619
pubmed: 28110218
Pharmacol Ther. 2020 Feb;206:107447
pubmed: 31756363
J Control Release. 2010 Aug 3;145(3):182-95
pubmed: 20226220
BMC Cancer. 2018 Sep 20;18(1):906
pubmed: 30236083
Magn Reson Med. 2013 Jan;69(1):255-62
pubmed: 22374813
CA Cancer J Clin. 2023 May-Jun;73(3):233-254
pubmed: 36856579
Int J Nanomedicine. 2020 Jul 30;15:5445-5458
pubmed: 32801699
NMR Biomed. 2005 Oct;18(6):383-9
pubmed: 16013087
Gastroenterology. 2010 Jun;138(6):2044-58
pubmed: 20420945
Transl Oncol. 2021 Oct;14(10):101174
pubmed: 34243011